Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
Completed
University Hospital Tuebingen
Phase 4
2005-06-01
Topical treatment of mild to moderate actinic keratosis located on the face and head with
Solaraze® is known to be a safe and efficient treatment option. However, it is unclear if an
expansion of the treatment period to 6 months will increase the rate of complete responses.
Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic
keratosis with Solaraze® applied twice daily to the face and head over 3 or 6 months of
treatment.
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Completed
National Cancer Institute (NCI)
Phase 2
2007-01-01
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged
skin.
PURPOSE: This randomized phase II trial is studying the side effects and how well
eflornithine works compared with diclofenac, given alone or together, in treating patients
with sun-damaged skin.
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Completed
University of Arizona
Phase 2
2007-01-01
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged
skin.
PURPOSE: This randomized phase II trial is studying the side effects and how well
eflornithine works compared with diclofenac, given alone or together, in treating patients
with sun-damaged skin.
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
Completed
MEDA Pharma GmbH & Co. KG
Phase 4
2008-12-01
This clinical trial serves the purpose to compare the long-term effects of a treatment of
actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the
face or the scalp. In particular, it should be found out whether the healing effect of these
two medications on the skin lesions (i.e. the damaged skin parts) can be maintained for a
prolonged period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
